Xarelto (rivaroxaban) is a blood thinner drug that has now been linked to eye bleeding in a study that was published in June 2015 in the medical journal, JAMA Ophthalmology.
The study’s researchers found that the three patients who experienced spontaneous eye bleeding — also known as vitreous hemorrhage — had recently transitioned from warfarin to Xarelto, leading some to surmise that patients are at an elevated risk of eye bleeds and other uncontrolled bleeding when switching blood thinner drugs.
For patients on Xarelto, eye bleeding typically arises in the space between the retina and the lens. In the case of the patients who were examined in this particular study, the bleeding stopped spontaneously.
But had the bleeding continued unabated, the patients may have suffered serious complications, such as blindness and other damage that could have led to the removal of the individual’s eye.
Unlike Warfarin, which can be reversed with high doses of vitamin K, new generation anti-coagulant drugs such as Xarelto and Pradaxa do not have an antidote. Although it should be noted that uncontrolled bleeding on Pradaxa can be treated with emergency dialysis, which serves to cleanse the drug from the patient’s bloodstream. But this procedure is not effective with Xarelto, which has no antidote or other method of reversal.
Another form of Xarelto-related eye hemorrhage which was not examined in this particular study is called subconjunctival bleeding or “red eye.” A subconjunctival hemorrhage occurs in the sclera, better known as the whites of your eye, which contain visible blood vessels which can rupture.
In the case of subconjunctival eye bleeds, the bleeding occurs in the whites of the eye in the space between the eye’s outer layer (called the conjunctiva) and the sclera. The iris (the colored part of the eye) is not affected, nor is the individual’s vision in most cases, assuming the bleeding ceases on its own.
Just as in the case of a vitreous hemorrhage, if the “red eye” bleeding continues unabated, the patient may experience blindness and other painful complications that could warrant the eye’s removal.
Other Xarelto Bleeding Studies
This recent study on eye bleeding and Xarelto isn’t alone. Another study published in April 2015 revealed that patients taking Xarelto had a 200% increase in the risk of stomach bleeding compared to patients who were taking warfarin.
The average age of patients who had a fatal Xarelto bleeding incident was 82; a majority of non-fatal gastrointestinal bleeds occurred in patients over age 75 in nearly 3 out of 4 cases.
Find Out if You Have a Xarelto Case
If you or a family member experienced uncontrolled bleeding, including eye hemorrhaging from Xarelto, you may have a legal right to receive financial compensation. Numerous Xarelto lawsuits
have been filed, with patients awarded millions for their losses, including pain and suffering, medical expenses, lost wages and funeral expenses.
Contact The Meldofsky Firm today for a confidential and free case evaluation. Remember, the law limits how length of time you have to take legal action, so call today to ensure you don’t miss your opportunity to find justice! Call The Meldofsky Firm at (877) 274-8672.